Announcements Trials
Browse Landscape

Phase

Phase 3 28Phase 2 23Phase NA 3Phase 1/2 2Phase 1 2Phase 2/3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Leukemia, Myeloid, Acute 17Leukemia 11Myelodysplastic Syndromes 10Recurrence 8Lymphoma 8Burkitt Lymphoma 8Leukemia, Biphenotypic, Acute 7Multiple Myeloma 6Osteosarcoma 5Lymphoma, Non-Hodgkin 5Sarcoma 4Lymphoma, T-Cell 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Hodgkin Disease 4Hematologic Neoplasms 4Primary Myelofibrosis 3Neoplasms, Plasma Cell 3Leukemia, Myeloid 3Leukemia, Lymphocytic, Chronic, B-Cell 3Waldenstrom Macroglobulinemia 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphoid 2

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 39Docetaxel 38palbociclib 36Carboplatin 33Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × Methotrexate × Clear all
NCT02897700 2024-04-17

COC-IDCB

Shanghai Jiao Tong University School of Medicine

Phase 1 Recruiting
300 enrolled
Breast

Breast Neoplasms

NCT00496665 2013-11-18

ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
25 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡